The Learning Portal will be under maintenance Saturday, 8 August between 6 AM and 6 PM EST. Portal functionality will be unavailable during this window.
We apologize for any inconvenience caused during this time.

RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > 2019 > 7 > Patient Registries May Prove Valuable in Regulatory Decisions, EMA Study Finds

Patient Registries May Prove Valuable in Regulatory Decisions, EMA Study Finds

Posted 18 July 2019 | By Zachary Brennan 

Patient Registries May Prove Valuable in Regulatory Decisions, EMA Study Finds

Although patient registries can be heterogenous in their quality and design, a new study in Drug Safety co-authored by a European Medicines Agency (EMA) official explains how patient registries could provide valuable data for regulatory decisions.

The authors explain how such registries can be used when randomized controlled trials are not feasible, such as with some rare diseases, or to meet postmarketing commitments.

“For products granted conditional marketing approval, registry studies may provide post-authorisation data to fulfil regulator-imposed specific obligations to confirm safety and/or effectiveness, as is the case with the recently authorised chimeric antigen receptor (CAR) T-cell products, tiagenlecleucel and axicabtagene ciloleucel,” the study says.

The eight authors, from EMA, Queens Mary University of London, the University of Groningen in the Netherlands and the Dutch Medicines Evaluation Board, also explain how registries are currently underused.

Of 335 products recommended for approval by EMA’s Committee for Medicinal Products for Human Use between 2005 and 2013, 31 registries were requested to fulfill a condition of the marketing authorization, but by December 2017, just ten had been completed.

To try to figure out what factors facilitate registry use, the authors synthesized observations and recommendations published in five reports arising from a multi-stakeholder EMA consultation and four disease-specific workshops conducted as part of EMA’s Patient Registries Initiative.

The study explains how the absence or incompleteness of 10 different factors “greatly impeded registry use.”
Such factors include the use of common core data sets, common data coding terminologies, data access and sharing and data linkage capacity, among others.

“From a regulatory perspective, the ultimate requirement of patient registries is that they permit the conduct of high-quality studies that evaluate the safety and effectiveness of medicines. Recognising the benefits and challenges inherent in using observational data for medicines assessments, in 2019, EMA will publish methodological and operational advice on handling registry data in post-authorisation studies, taking into account responses to its open consultation on a preliminary discussion paper,” the study adds.

Patient Registries: An Underused Resource for Medicines Evaluation

Regulatory Focus newsletters

All the biggest regulatory news and happenings.